A Phase 2 interventional study of MCI-186 and Placebo in Acute Ischemic Stroke (AIS), sponsored by Shionogi. Completed at 3 sites in 3 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Shionogi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Ischemic Stroke with a site in Finland — 6 open to participants now, 10 under way, 1 of them phase 3. Ischemic Stroke · Finland.
Among the 38 studies in Ischemic Stroke with a site in Finland, this one is the 27th largest by enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2009, is one of 7 in phase 2, and was the 5th registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →6 of the 38 studies in Ischemic Stroke with a site in Finland are open now. Recruiting first, the newest first:
Karolinska Institutet · Sites in Finland, Sweden
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Finland, Austria, Belgium and 9 more countries
Ages 18+
Finnish Institute of Occupational Health · Sites in Finland
Ages 18–68
University Hospital, Basel, Switzerland · Sites in Finland, United States, Argentina and 6 more countries
Ages 18+ · Women only
Jukka Putaala · Sites in Finland
Ages 40+
A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 495 across the 30 interventional studies, 1,200 across the 8 observational. Of the 24 that completed or were terminated, 8 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 38 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 3 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
1 of the studies in Ischemic Stroke with a site in Finland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06709898Finnish Institute of Occupational HealthStroke in Working Age and Job Accommodation in Facilitating Transition Back to Work | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies in Ischemic Stroke with a site in Finland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MCI-186
Drug: Placebo
Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion
Also known as: Edaravone
Cohort1:circa 1000mg / 72-hour infusion matching placebo Cohort2:circa 2000mg / 72-hour infusion matching placebo
Number of Participants That Experienced Adverse Events
Additional Outcome Measures are included in Tables for Serious Adverse Events and Other Adverse Events to report their numbers and frequency.
Time frame: 87days
Plasma MCI-186 Pharmacokinetics
The geometric mean values of MCI-186 plasma concentration at the end of the infusion (at 72h) in cohorts 1 and 2 were determined.
Time frame: 72 hours
mRS, NIHSS, Barthel Index
Time frame: throughout study
| Milestone | MCI-186 Cohort1 | MCI-186 Cohort2 | Placebo Group |
|---|---|---|---|
| Started | 12 | 13 | 11 |
| Completed | 12 | 13 | 11 |
| Not completed | 0 | 0 | 0 |
Additional Outcome Measures are included in Tables for Serious Adverse Events and Other Adverse Events to report their numbers and frequency.
| participants | MCI-186 Cohort1 | MCI-186 Cohort2 | Placebo Group |
|---|---|---|---|
| Deaths | 0 | 0 | 0 |
| Serious Adverse Events | 0 | 2 | 1 |
| Other Adverse Events | 12 | 10 | 10 |
The geometric mean values of MCI-186 plasma concentration at the end of the infusion (at 72h) in cohorts 1 and 2 were determined.
| ng / ml | MCI-186 Cohort1 | MCI-186 Cohort2 |
|---|---|---|
| Plasma MCI-186 Pharmacokinetics | 391 ± 24.21 | 1595 ± 51.57 |
Results for this outcome have not been posted.
Collected over 87 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MCI-186 Cohort1 | — | 0/12 (0%) | 12/12 (100%) |
| MCI-186 Cohort2 | — | 2/13 (15.4%) | 10/13 (76.9%) |
| Placebo Group | — | 1/11 (9.1%) | 10/11 (90.9%) |
| Event | MCI-186 Cohort1 | MCI-186 Cohort2 | Placebo Group |
|---|---|---|---|
| HemiparesisNervous system disorders | 0/12 | 0/13 | 1/11 |
| GoutMetabolism and nutrition disorders | 0/12 | 1/13 | 0/11 |
| Ischaemic StrokeNervous system disorders | 0/12 | 1/13 | 0/11 |
| Event | MCI-186 Cohort1 | MCI-186 Cohort2 | Placebo Group |
|---|---|---|---|
| NauseaGastrointestinal disorders | 5/12 | 1/13 | 2/11 |
| HeadacheNervous system disorders | 4/12 | 4/13 | 4/11 |
| HypertensionVascular disorders | 3/12 | 2/13 | 4/11 |
| ConstipationGastrointestinal disorders | 1/12 | 0/13 | 2/11 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 0/12 | 0/13 | 2/11 |
| HyperlipidaemiaMetabolism and nutrition disorders | 2/12 | 0/13 | 0/11 |
| Atrial FibrillationCardiac disorders | 0/12 | 2/13 | 0/11 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/12 | 2/13 | 0/11 |
| CataractEye disorders | 0/12 | 0/13 | 1/11 |
| Vision BlurredEye disorders | 0/12 | 0/13 | 1/11 |
| Age, Categorical(Participants) | MCI-186 Cohort1 | MCI-186 Cohort2 | Placebo Group | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 9 | 2 | 16 |
| >=65 years | 7 | 4 | 9 | 20 |
| Sex: Female, Male(Participants) | MCI-186 Cohort1 | MCI-186 Cohort2 | Placebo Group | Total |
|---|---|---|---|---|
| Female | 2 | 4 | 3 | 9 |
| Male | 10 | 9 | 8 | 27 |
Ran from Feb 2009 to primary completion in Nov 2010, 21 months.
Results were first posted in May 2014, 3 years 5 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's 21 months is below that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edaravone